Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KYN 5356 (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kynexis

Most Recent Events

  • 14 Nov 2025 According to a Cognision media release, the company has entered into a partnership with Kynexis to utilize the COGNISION System in this Phase 2 clinical trial of KYN-5356 in subjects with schizophrenia, to precisely measure drug-induced changes in brain function. The measurements are obtained during EEG and ERP testing sessions done after the administration of either KYN-5356 or a placebo and help in linking therapeutic effects with objective biomarkers related to the MOA and disease biology.
  • 30 Sep 2025 According to Kynexis media release, the first patient has been dosed in this trial, topline results are expected by Q4 2026
  • 25 Sep 2025 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top